Bendroflumethiazide (CAS 73-48-3)
QUICK LINKS
Bendroflumethiazide is a thiazide diuretic that functions by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubules of the kidneys. This leads to increased excretion of water, sodium, chloride, and potassium, resulting in diuresis. Bendroflumethiazide′s mode of action involves binding to the sodium-chloride symporter in the renal tubules, thereby blocking the reabsorption of these ions. This disruption of ion transport ultimately leads to the elimination of excess fluid and electrolytes. At the molecular level, bendroflumethiazide acts by interfering with the normal functioning of ion channels and transporters, altering the balance of electrolytes and water. Bendroflumethiazide′s mechanism of action is integral to understanding its impact on fluid and electrolyte balance in experimentation.
Bendroflumethiazide (CAS 73-48-3) References
- A clinical trial of bendroflumethiazide in the elderly. | COLLINS JA, JR. 1962. J Am Geriatr Soc. 10: 671-6. PMID: 13880590
- RAUWOLFIA-BENDROFLUMETHIAZIDE IN THE TREATMENT OF HYPERTENSION. | REID, WJ. 1965. J Am Geriatr Soc. 13: 365-71. PMID: 14279104
- Interaction of human serum albumin with bendroflumethiazide studied by fluorescence spectroscopy. | Pang, YH., et al. 2005. J Photochem Photobiol B. 80: 139-44. PMID: 15916901
- Characterisation of excipient-free nanoporous microparticles (NPMPs) of bendroflumethiazide. | Healy, AM., et al. 2008. Eur J Pharm Biopharm. 69: 1182-6. PMID: 18595674
- Life-threatening hyponatraemia. | Egom, EE., et al. 2011. BMJ Case Rep. 2011: PMID: 22696760
- The effect of indapamide vs. bendroflumethiazide for primary hypertension: a systematic review. | Macfarlane, TV., et al. 2019. Br J Clin Pharmacol. 85: 285-303. PMID: 30312512
- Effects of bendroflumethiazide on bone mineral density; results from the BONATHIAD randomized double-blind placebo-controlled cohort study. | Emmanuel, T., et al. 2020. Bone Rep. 13: 100737. PMID: 33318971
- Associations of thiazide use with skin cancers: a systematic review and meta-analysis. | Shao, SC., et al. 2022. BMC Med. 20: 228. PMID: 35794547
- Preclinical safety evaluation of the nadolol/bendroflumethiazide combination in mice, rats, and dogs. | Stevens, AC., et al. 1984. Fundam Appl Toxicol. 4: 360-9. PMID: 6745529
- Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. | Schäfer-Korting, M. and Mutschler, E. 1982. Eur J Clin Pharmacol. 21: 315-23. PMID: 7056277
- Pharmacokinetics of bendroflumethiazide after low oral doses. | Borgström, L., et al. 1981. J Pharmacokinet Biopharm. 9: 431-41. PMID: 7310642
- Pharmacokinetics of bendroflumethiazide. | Beermann, B., et al. 1977. Clin Pharmacol Ther. 22: 385-8. PMID: 902450
- Investigations on the antihypertensive activity of timolol and bendroflumethiazide and the combination in dogs and rats. | Nielsen, KC., et al. 1976. Acta Pharmacol Toxicol (Copenh). 39: 500-12. PMID: 990034
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bendroflumethiazide, 1 g | sc-233928 | 1 g | $55.00 |